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Circulation: Arrhythmia and Electrophysiology

ORIGINAL ARTICLE

Plasticizer Interaction With the Heart
Chemicals Used in Plastic Medical Devices Can Interfere With
Cardiac Electrophysiology

See Editorial by Reilly et al
BACKGROUND: Phthalates are used as plasticizers in the manufacturing
of flexible, plastic medical products. Patients can be subjected to high
phthalate exposure through contact with plastic medical devices. We
aimed to investigate the cardiac safety and biocompatibility of mono-2ethylhexyl phthalate (MEHP), a phthalate with documented exposure in
intensive care patients.
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METHODS: Optical mapping of transmembrane voltage and pacing
studies were performed on isolated, Langendorff-perfused rat hearts to
assess cardiac electrophysiology after MEHP exposure compared with
controls. MEHP dose was chosen based on reported blood concentrations
after an exchange transfusion procedure.
RESULTS: Thirty-minute exposure to MEHP increased the atrioventricular
node (147 versus 107 ms) and ventricular (117 versus 77.5 ms) effective
refractory periods, compared with controls. Optical mapping revealed
prolonged action potential duration at slower pacing cycle lengths, akin
to reverse use dependence. The plateau phase of the action potential
duration restitution curve steepened and became monophasic in MEHPexposed hearts (0.18 versus 0.06 slope). Action potential duration
lengthening occurred during late-phase repolarization resulting in
triangulation (70.3 versus 56.6 ms). MEHP exposure also slowed epicardial
conduction velocity (35 versus 60 cm/s), which may be partly explained
by inhibition of Nav1.5 (874 and 231 µmol/L half-maximal inhibitory
concentration, fast and late sodium current).
CONCLUSIONS: This study highlights the impact of acute MEHP
exposure, using a clinically relevant dose, on cardiac electrophysiology
in the intact heart. Heightened clinical exposure to plasticized medical
products may have cardiac safety implications—given that action potential
triangulation and electrical restitution modifications are a risk factor for
early after depolarizations and cardiac arrhythmias.
VISUAL OVERVIEW: A visual overview is available for this article.
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WHAT IS KNOWN?
• Phthalate chemical exposure has been reported in
patients undergoing invasive medical procedures
that use large quantities of plastic materials.
• We previously reported that phthalate chemical
exposure impairs cell coupling and slows conduction velocity in a cardiomyocyte cell model.

WHAT THE STUDY ADDS?
• Acute phthalate exposure slowed atrioventricular
conduction and increased atrioventricular node
effective refractory period in an intact, whole heart
model.
• Phthalate exposure prolonged action potential
duration time, enhanced action potential triangulation, and increased the ventricular effective
refractory period.
• Phthalate exposure slowed epicardial conduction
velocity, which may be partly explained by inhibition of Nav1.5.

P
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lastics have revolutionized clinical care. Yet, despite
the many advantages, concerns have been raised
about the ubiquitous use of plastics in the clinical setting.1–3 To manufacture flexible plastic products,
phthalate esters are added to impart flexibility to otherwise stiff polyvinyl chloride polymers. Di-2-ethylhexyl
phthalate (DEHP) is the most commonly used plasticizer
in Food and Drug Association–approved medical devices, including blood storage bags, tubing circuits, enteral feeding tubes, endotracheal tubes, and catheters.4 In
the finished product, DEHP can contribute up to 40%
by weight in intravenous bags and 80% by weight in
medical tubing. Because phthalate esters are hydrophobic and noncovalently bound to the polyvinyl chloride
polymer, these additives are highly susceptible to leaching when in contact with blood, plasma, and other lipophilic solutions.5,6 Consequently, heightened phthalate exposure has been observed in patients undergoing
invasive medical procedures that use large quantities of
plastic materials—including cardiopulmonary bypass,
extracorporeal membrane oxygenation, dialysis, and
transfusion procedures (see Table).7–21 As an example,
a neonatal exchange transfusion procedure resulted in
plasma concentrations as high as 38 µM DEHP and 54
µM mono-2-ethylhexyl phthalate (MEHP), the primary
metabolite of DEHP.13 Whereas multiple medical procedures can increase a patient’s cumulative phthalate
exposure to levels that are 4000× to 160 000× higher
than deemed safe.7 Importantly, phthalate levels can
remain elevated in the blood for hours (eg, blood transfusion; 5–24 hour half-lives)22,23 to weeks (eg, extracorporeal membrane oxygenation support, intensive care
unit patient) depending on the course of treatment.19

Incidental plastic chemical exposure during medical
procedures is virtually unavoidable, yet the direct impact
on patient health remains unclear. Because phthalates
structurally resemble natural hormones, they can exert
endocrine-disrupting properties and interfere with an
array of biological processes.7,24,25 Moreover, these low
molecular weight chemicals have been shown to interact with ion channels, nuclear receptors, and other cellular targets. Accordingly, phthalates are likely to have
a global impact on human health that is multifactorial.
Indeed, epidemiological studies have reported associations between phthalate exposure and a broad range
of health conditions, including metabolic disturbances,
reproductive disorders, inflammatory conditions, neurological disorders, and cardiovascular disease.24–31 The
latter is particularly worrisome—since patients who are
most susceptible to hospital-based phthalate exposures
are often at heightened risk for cardiovascular complications, including those undergoing multiple transfusions, chronic transfusions (sickle cell, thalassemia) or
support procedures (extracorporeal membrane oxygenation, cardiopulmonary bypass, dialysis).4,9,19,32–34 Local
and systemic reactions to plastic chemicals may add
an extra insult to patients who are prone to secondary complications, including hypoxia (congenital heart
defect patients), ischemia-reperfusion injury (cardiac
surgery patients), postoperative arrhythmias, cardiac
iron overload, pulmonary hypertension, impaired contractility, and diastolic dysfunction.
Indeed, animal studies have shown a causal relationship between phthalate exposure and subsequent
alterations in cardiovascular function.35–39 Using a
rodent heart-lung preparation, Labow, et al38 showed
that phthalates exert a hypertensive effect on the
pulmonary vasculature. This group also showed that
phthalate exposure has a negative inotropic effect on
isolated human atrial trabeculae, thus highlighting the
applicability to humans.36 Our group has also shown
that phthalate exposure alters calcium handling and
contractility in vitro, using rodent and human cardiomyocytes.40,41 Moreover, phthalate exposure was
shown to reduce gap junctional connexin-43,40,41 which
decreased intercellular coupling and slowed conduction
velocity (CV). Therefore, we hypothesized that phthalate exposure may directly impact cardiac electrophysiology in an intact heart.
To test this hypothesis, we comprehensively assessed
the electrophysiological effects of MEHP using isolated,
intact rodent hearts. Cardiac electrophysiology parameters were measured at baseline and again after treatment with either control or MEHP-supplemented media
perfusion (30 minutes). To address clinical relevance,
the MEHP dose (60 µM) selected for heart perfusion
was comparable to patient exposure after an exchange
transfusion procedure13 or measured levels in stored
blood products.4,42
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METHODS

Table. Measurements of Clinical Exposure to DEHP and Its
Metabolites Including MEHP
Description
Child, blood products
(blood)

Concentration

Reference

6.4–29 µg/mL DEHP (RBC unit)
27.6–405 µg/mL DEHP (plasma unit)

Mallow et al7

34.2–61.4 µg/mL DEHP (platelets)
Child, exchange
transfusion (blood)

1.1–15.6 µg/mL MEHP
2.3–19.9 µg/mL DEHP

Child, blood products
(blood)

3.0–15.6 µg/mL MEHP (blood unit)

Child, ECMO (blood)

26.8 µg/mL DEHP (14 days)

36.8–84.9 µg/mL DEHP (blood unit)

33.5 µg/mL DEHP (24 days)
Child, ECMO (blood)

10–30.8 µg/mL DEHP (circuit)
0–24.18 µg/mL DEHP (patient)

Child, blood products
(blood)
Child, intensive care
unit (urine)

4.3–123 µg/mL DEHP (blood unit)
6–21.6 µg/mL DEHP (patient)

Sjöberg et al
19858
Sjöberg et al
198513
Shneider et al14

Karle et al15

Plonait et al16

577–2357 µg/L MECPP
120–438 µg/L MEHHP
72–306 µg/L MEOHP

Gaynor et al17

14.9–49.5 µg/L MEHP
Child, intensive care
unit (urine)

6.2–704 ng/mL MEHP (5th%–
95th%)
290–13 161 ng/mL MEHHP
(5th%–95th%)

Calafat et al
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0–1234 ng/mL MEHP
0–5841 ng/mL MEOHP

Demirel et al19

0–5086 ng/mL MEHHP
Child, intensive care
unit (urine)
Adult, blood
products (blood)
Adult, intensive care
unit (blood)

0.049–1.273 µg/mL
1.1–18.7 µg/mL MEHP
72.5–295.2 µg/mL DEHP

Su et al20
Peck et al10

0–171 µg/L MECPP
0–55.4 µg/L MEHHP

Huygh et21

0–22.9 µg/L MEOHP
Adult, ECMO +
CVVH (blood)

17.2–5194 µg/L MECPP

Adult, coronary
bypass (blood)

15.4–72.9 mg/d DEHP

0–880 µg/L MEHHP

Huygh et al21

3.3–305 µg/L MEOHP

Adult, heart
transplantation (blood)
Adult, hemodialysis
(blood)
Adult, hemodialysis
(blood)

2.2–8 mg/kg MEHP
2.3–167.9 mg/d DEHP
0.25–18.8 mg/d MEHP
0.3–7.6 µg/mL DEHP
0.9–2.83 µg/mL MEHP
2–3 µg/mL DEHP

Isolated Heart Preparation
Animal protocols were approved by the Institutional Animal
Care and Use Committee of the Children’s Research Institute
and followed the National Institutes of Health’s Guide for
the Care and Use of Laboratory Animals. Experiments were
conducted using adult, male Sprague-Dawley rats (>8 weeks
old, >280 g, Taconic Biosciences). Animals were housed in
conventional rat cages in the Research Animal Facility under
standard environmental conditions (12:12 hour light:dark
cycle, 64°C–78°C, 30%–70% humidity, free access to reverse
osmosis water, corn cob bedding, and food [2918 rodent
chow; Envigo]). Animals were anesthetized with 3% to 5%
isoflurane; the heart was excised and then transferred to a
temperature-controlled (37°C) constant-pressure (70 mm Hg)
Langendorff perfusion system for electrophysiology and optical mapping experiments. Excised hearts were perfused with
Krebs-Henseleit buffer bubbled with carbogen throughout
the duration of the experiment, as previously described (≈1
hour).43

General Protocol
18

243–10 413 ng/mL MEOHP
(5th%–95th%)
Child, intensive care
unit (urine)

The authors declare that data that supports the findings of
this study are available within the article.

MEHP (93+%; Wako Chemicals) stock solution was prepared
in 99+% dimethyl sulfoxide (DMSO), and the working concentration was prepared directly in perfusate media with a
total DMSO concentration of <0.001%. To avoid bolus exposure, the perfusion system was designed to premix MEHP with
perfusate media to the desired concentration before entering the aorta. Cardiac electrophysiology was assessed under
baseline conditions (control media perfusion) and again after
either control media perfusion or 60 µM MEHP-supplemented
media perfusion (30 minutes). This allowed us to control for
electrophysiology changes that could be attributed to procedure (control baseline versus control 30 minutes), individual
animal differences, and MEHP treatment (control 30 minutes
versus MEHP 30 minutes). For clinical relevance, the MEHP
dose (60 µM) was selected based on an upper clinically relevant exposure after an exchange transfusion procedure13
and within the range of measured levels in stored blood
products.4,42

Electrophysiology Measurements
Barry et al9

Barry et al9

Pollack et al11
Faouzi et al12

CVVH indicates continuous venovenous hemofiltration; DEHP, di-2ethylhexyl phthalate; ECMO, extracorporeal membrane oxygenation;
MECPP, mono-2-ethyl-5-carboxypentyl phthalate; MEHHP, mono-2-ethyl-5hydroxyhexyl phthalate; MEHP, mono-2-ethylhexyl phthalate; MEOHP, mono2-ethyl-5-oxohexyl phthalate; and RBC red blood cell.

A reference electrode was positioned proximal to the right
atrium and a measuring electrode proximal to the apex to
acquire a pseudo-ECG in the lead II configuration (differential
amplifier with 1000× gain). During sinus rhythm, ECG signals were collected to analyze heart rate, beat rate variability,
atrioventricular conduction (PR interval) depolarization time,
and repolarization time (RJpoint, RT).44 Signals were acquired in
iox2 (emka Technologies), and ECG segments were computed
in ecgAUTO (emka Technologies).
For determination of atrioventricular nodal effective
refractive period (AVNERP), Wenckebach cycle length (WBCL),
and sinus node recovery time, a coaxial stimulation electrode
(Harvard Apparatus, Holliston, MA) was placed on the right
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atrium. AVNERP was defined as the maximum extrastimulus
interval (S1-S2) during atrial pacing that failed to conduct
through the atrioventricular node, as indicated by loss of
ventricular capture. WBCL was defined as the maximum pacing cycle length (PCL) during atrial pacing that caused the
Wenckebach phenomenon. Sinus node recovery time was
measured to assess the automaticity of the sinoatrial node
and defined as the time delay between the last paced atrial
depolarization and the first sinus beat (5 s electrical stimulation at 200 ms PCL). A stimulator (Bloom Electrophysiology,
Denver, CO) was set to 1 ms pulse width at 1.5× diastolic
current threshold. For ventricular pacing, a 0.25 mm diameter
tungsten, unipolar, cathodal electrode was placed on the LV
epicardium and centered in the imaging field. A stainless steel
indifferent electrode was placed under the heart. To determine the ventricular effective refractory period (VERP) within
10 ms, dynamic pacing (S1-S1) was performed during optical mapping. An arrhythmia score was designated for each
individual heart after the dynamic pacing protocol, wherein
the most severe electrical disturbance was classified (1=single premature ventricular contraction [polyvinyl chloride],
2=bigeminy/salvos, 3=ventricular tachycardia or fibrillation).45

Ventricular Conduction Frequency
Composition Assessment
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High resolution (2000 Hz) unfiltered digital pseudoECG recordings were analyzed using a custom MATLAB
(MathWorks, Inc, Natick, MA) software application. Normal
sinus median beat was constructed out of 436 normal sinus
beats, as previously described.46 Appropriate selection of
beats was confirmed by investigator (Dr Perez-Alday) with the
aid of a graphical display. From the median beat obtained,
QRS was measured from QRS onset to J point.47 The power
spectral density (PSD) was measured on the median beat of
the ECG signal48 using a nonparametric Fast-Fourier transform algorithm based on the Welch-Bartlett power estimation method,49 with a Hanning window of length 8 samples
and a 50% overlap between segments. From the Nyquist frequency, the available frequency range was from 0 to 1000
Hz; however, the frequency composition was calculated on 5
subsets of 100 Hz frequency intervals from 0 Hz to 500 Hz.
The relative contribution of frequencies was normalized over
the total power.

Optical Mapping
After establishing a baseline heart rate (10 minutes), the perfusate was supplemented with 10 µmol/L (−)-blebbistatin
(Sigma-Aldrich) to reduce motion artifact for imaging experiments.50 The heart was loaded with a potentiometric dye (62.1
µg RH237, 1-minute staining) through a bubble trap located
proximal to the aortic cannula.51,52 The epicardium was illuminated with 2 broad light-emitting diode spotlights (530 nm,
200 mW; Mightex). RH237 fluorescence was longpass filtered
(680+ nm; Chroma Technologies), and optical action potentials
were acquired using a fixed focal lens (17 mm, f/0.95; Schneider
Optics) attached to an sCMOS camera (Zyla 4.2 PLUS; Andor
Technology). The camera sensor was cropped to 384×256 pixels and set to an exposure time of 1.219 ms resulting in the
acquisition of 16-bit monochrome images at 814 frames per

second for 2 s. Optical maps were acquired during each PCL
(S1-S1; 250–80 ms, 10 ms increments). A custom MATLAB
(MathWorks, Natick, MA) script was used to calculate the action
potential durations (APD) to percent repolarization (APD30, 80,
90) for every beat in the recording, as previously described. APD
triangulation was defined as the difference between APD90 and
APD30.53 Restitution curves were generated by plotting APD80
against PCL; curves were then analyzed as either monophasic
or biphasic (where applicable) to determine slopes, as indicated
by Franz.54 APD alternans were defined as sequential APD80
measurements that differed by >4 ms.

Image and Signal Processing
Data analysis was performed using a custom MATLAB script. A
region of interest (<20 pixel radius) was selected from the raw
image, averaged, and plotted against time. Drift removal was
performed by subtraction of a polynomial fit if necessary. To
remove high-frequency noise, a fifth order Butterworth lowpass filter was applied to the resulting signals with a cutoff
frequency adjusted between 50 and 150 Hz. A peak detector
was then used to measure the total number of action potentials in the file across time. Characteristics from each event
are measured and averaged, including APD30, APD80, and
APD90, as described previously. Image processing was performed, and isochrone activation maps were constructed in
RHYTHM.55 The background was removed, convolved with a
15×15 uniform kernel for box blurring and then time signals
were low-pass filtered below 100 Hz. The activation time of
every pixel on the heart was defined as the maximum derivative of the action potential or transient upstroke. To measure
epicardial CV, activation maps were subsequently loaded into
ORCA56 and measured at a minimum of 18 angles separated
by 10° each from the pacing stimulus with the median CV
reported. Subsequent electrical wave propagation images
were then constructed using custom Python scripts and plotted with matplotlib.57

Whole-Cell Voltage-Clamp Recordings
Recordings were performed at room temperature (22°C–
25°C) using HEK293 (human embryonic kidney 293) cells
stably transfected with Nav1.5 cDNA. For Nav1.5 recordings,
the extracellular solution (mM) included 137 NaCl, 10 HEPES,
4 KCl, 1 MgCl2, 1 CaCl2, 10 dextrose, and the intracellular
solution included 120 aspartic acid, 120 CsOH, 10 CsCl, 10
HEPES, 10 EGTA, 5 MgATP, 0.4 TrisGTP. The voltage protocol (1
s duration) was repeated at 0.1 Hz. Briefly, cells were repolarized from −95 to −120 mV for 200 ms, then depolarized from
−120 to −15 mV for 40 ms, and further depolarized to +40
mV for 200 ms, followed by a voltage ramp down phase for
100 ms from +40 to −95 mV. Nav1.5 late current was induced
by 20 nmol/L anemone toxin in the extracellular solution,
which allowed for the study of late sodium current contribution from Nav1.5 that is separate from fast sodium current,
as previously described.58 Nav1.5 fast current was measured
in the absence of anemone toxin. For positive control, 30 µM
tetrodotoxin (sodium channel blocker) was directly applied
to recordings and resulted in 98.3±0.7% Nav1.5 current
block (n=3). To ensure baseline recording was stable enough
for drug application, cells were presented with this voltage
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Figure 1. Effect of mono-2-ethylhexyl phthalate (MEHP) on ECG characteristics during sinus rhythm.
A, Experimental protocol timeline; all ECG recordings were performed during sinus rhythm. B, ECG signals collected from excised, intact rat hearts with PR
interval denoted. C, Heart rate (HR) decreased with time of perfusion and after application of blebbistatin for mechanical uncoupling, with no difference
between treatment groups. D, Similar rate slowing was observed in the RR interval, and coincided with heart rate variability changes in E SD of the normal
RR intervals (SDNN) and (F) root means successive square difference (rMSSD) after 30-min perfusion. G and H, Prolonged depolarization and repolarization in
MEHP-exposed hearts as measured from R to J inflection point (RJpoint) and R to T-wave (RT) (G) PR interval time was significantly lengthened in MEHP-exposed
hearts compared to both baseline and control (Ctrl) hearts after the same duration of perfusion (P<0.05). n≥7 per group. BPM indicates beats per minute; and
EP, electrophysiology protocol.
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protocol in control solution until Nav1.5 current amplitudes
for 12 consecutively recorded current traces (2-minute duration) exhibit <10% difference. Effects were monitored for 3
minutes before and after application of MEHP (n=4 per dose).
To quantify drug potency against Nav1.5 channels, the steady
state Nav1.5 current amplitude (averaged value from 5 steady
state current traces) in drug solution was divided by the averaged amplitude from the last 5 traces measured in control
solution to calculate the fractional block. Then, fractional
block was plotted against drug concentration tested, fitted
with the Hill Equation to generate an half-maximal inhibitory
concentration (IC50) and the Hill coefficient.

In Silico Modeling
Human ventricular action potentials were simulated using
previously established models and conductance.59,60 The
block of fast and late sodium, INa and INaL, respectively, were
provoked with the computed IC50 from MEHP determined
by whole-cell recordings (see previous section) as previously
described.62 The isolated epicardial cellular model was paced
with 1000 pulses (−80 µA/µF, 0.5 ms) at PCL=250 ms in the
presence of 60 µmol/L MEHP.

Statistical Analysis
Statistical analysis was performed using the R software package and Stata MP 15.1 (StataCorp, College Station, TX).
Data normality was confirmed by Shapiro-Wilk test. Datasets
were compared using a 2-sample Student independent t test

between the 2 treatment groups (30-minute control, 30-minute MEHP treated) or paired t test between baseline and
30-minute time points. Significance was defined as P≤0.05.
Results were reported as mean±SE mean, from a minimum
of 5 animals per group as indicated. As distribution of PSD
variables was skewed, we used Wilcoxon rank-sum test to
compare groups (control versus MEHP treated). Wilcoxon
matched-pairs signed-ranks test was used for paired comparison of PSD changes before and after MEHP treatment.
Variables with skewed distribution are presented as median
and interquartile range. Arrhythmia incidence was compared
using the χ2 test.

RESULTS
Effects of MEHP Exposure on Cardiac
Automaticity and Beat Rate Variability
During Sinus Rhythm
ECG characteristics were quantified at 2 time points—
first under baseline conditions and again after 30
minutes of control or 60 µM MEHP-supplemented
media perfusion during sinus rhythm (Figure 1A).
Example ECG traces are shown in Figure 1B. Heart
rate at 30 minutes was comparable between experimental groups, 172 beats per minute in control and
178 beats per minute in MEHP-treated hearts (Fig-
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Figure 2. Sinus node function and atrioventricular conduction altered after mono-2-ethylhexyl phthalate (MEHP) treatment.
A, ECG trace corresponding to a 200 ms pacing cycle length (PCL) train (indicated by arrows) on the right atrium in a control (Ctrl) heart. Sinus node recovery
time (SNRT) is indicated as the delay between the cessation of pacing and the resumption of sinus node activity. B, SNRT measured in MEHP-treated heart shows
marked prolongation compared with Ctrl. C, Aggregate SNRT analysis for MEHP-treated hearts and time-matched Ctrls (P<0.05). D, Wenckebach cycle length
(WBCL) measured as the earliest PCL in which Wenckebach phenomenon was visible (P=0.07). E, Atrioventricular nodal refractory period (AVNERP) assessed by
S1-S2 pacing on the right atrium was significantly lengthened in MEHP hearts compared with Ctrls (P<0.05). n=5–8 per group.

ure 1C and 1D). Beat rate variability was assessed as a
cumulative index of automaticity and sinus node discharge. Although both root means successive square
difference and SD of the normal RR intervals trended
higher in MEHP-treated hearts (9.4±2.4 and 17.3±4.2
ms, respectively) compared with controls (5.4±1.7 and
11.9±2.5 ms, respectively), neither parameter was
significant (root means successive square difference,
P=0.19; SD of the normal RR intervals, P=0.28) Figures 1E and 1F. MEHP treatment increased RJpoint and
RT intervals by 55% and 30%, respectively (Figure 2),
both readily identifiable indicators of depolarization
and repolarization in the excised rodent heart44 (Figures 1G and 1H). Atrioventricular conduction delay
was also measured during sinus rhythm. Atrioventricular conduction remained relatively stable in control
hearts, as indicated by a PR interval time of 43±2 ms
at baseline and 47±2 ms after 30-minute perfusion.
In comparison, the PR interval time increased by 44%

in MEHP-treated hearts (41±1 ms baseline, 59±3 ms,
P<0.05; Figure 1I).

Electrophysiological Study
Sinus node function was further investigated by measuring sinus node recovery time, which was delayed
by 54% in MEHP-treated hearts (532±57 ms) compared with control hearts (345±10 ms, P=0.01, Figure 2A through 2C). WBCL trended longer in MEHPtreated hearts compared with controls, 155.8±12.4
to 126.6±4.5 (P=0.07, Figure 2D). Atrioventricular
node conduction refractoriness was interrogated by
implementing an atrial pacing protocol to measure
AVNERP, which was significantly longer in MEHPtreated hearts compared with controls, 147±13 ms
to 107±4.4 ms (P<0.05, Figure 2E). These results suggest that MEHP may directly increase atrioventricular
nodal refractoriness.
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Figure 3. Mono-2-ethylhexyl phthalate (MEHP) causes action potential morphology changes with corresponding modification of the electrical
restitution curve.
A, MEHP exposure caused the restitution curve to change from a biphasic form to a monophasic form with no plateau phase. The slope of the plateau on the
control (Ctrl) heart was 0.06 compared with 0.18 in the MEHP hearts. B, Despite the similarities in the action potential duration at faster cycle lengths, the ventricular effective refractory period (VERP) was markedly prolonged in the MEHP-treated group (P<0.05). C, With rapid pacing (pacing cycle length [PCL]=140 ms),
the action potential duration (APD) appeared similar between the Ctrl and MEHP-treated groups: there were no difference between (D) APD30, (E) APD90, or (F)
AP triangulation. G, At slower cycle lengths (PCL=240 ms), the action potential morphology was quite different: while (H) APD30 was similar, (I) lengthening was
apparent in the late phase as shown by APD90 (P<0.05). J, The effect on APD90 with no change on APD30 caused an increase in the triangulation shape of the
AP after MEHP treatment (P<0.05). N=7 for each group. AP Tri indicates action potential triangulation; and Vm, transmembrane voltage.
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Effects of MEHP Exposure on Ventricular
Conduction and Refractoriness During
Sinus Rhythm
ECG frequency content was also analyzed during sinus
rhythm, as high frequencies during depolarization are
associated with abnormal or slowed conduction.47,62 In
MEHP-treated hearts, contribution of high frequencies
(400–500 Hz) was increased by 0.032% (interquartile
range, −0.008% to 0.20%), whereas in control group,
contribution of the same frequency band (400–500 Hz)
decreased by 0.06% (interquartile range, 0.04%–1.19%),
P=0.076. ECG lead placement among isolated hearts
proved difficult due to the lack of anatomic markers and
consistency in positioning of the heart relative to ECG
leads, making experimental variability between individual hearts high for PSD measurements. Follow-up studies
were performed using optical mapping, because APD and
VERP measurements may more accurately predict alterations in ventricular repolarization in the rodent heart.63

Effects of MEHP Exposure on Epicardial
Conduction and Refractoriness During
Epicardial Pacing
Optical mapping of transmembrane voltage signals was
performed to evaluate action potential shape and dura-

tion, using an epicardial pacing protocol. APD at 80%
repolarization (APD80) was assessed until VERP was
reached, and APD80 values were compared between
the timed control and MEHP-treatment group giving
rise to the electrical restitution curves (Figure 3A). Ventricular refractoriness was determined during our optical mapping protocol which involves ventricular pacing at both baseline and 30-minute conditions. VERP
was 51% longer in MEHP-treated hearts (117±9.5 ms)
compared with time-matched controls (77.5±5.5 ms,
P<0.05; Figure 3B). A longer refractory period suggests that MEHP exposure slows repolarization. MEHPtreated hearts displayed a monophasic restitution curve
with a slope of 0.18 throughout (steep portion only,
no plateau), as compared to controls which displayed
a biphasic shape (steep and plateau phases). The steep
slope of the controls was like that of the MEHP group
at 0.17, and the slope of the plateau phase was 0.06.
Importantly, monophasic restitution curves are associated with an increased risk of electrical alternans.54,64
With a lengthened VERP in MEHP-treated hearts, loss
of capture at PCLs <100 ms limited APD measurements
in the MEHP group.
APD30 and APD90 were measured to compute the
triangulation of the action potential. At a selected
fast PCL (140 ms), there were no significant differences between control and MEHP (Figure 3C). APD30
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Figure 4. Action potential alternans and arrhythmia susceptibility from mono-2-ethylhexyl phthalate (MEHP) exposure.
A, MEHP-treated hearts displayed increased susceptibility to alternating action potential morphology at the same pacing cycle length (PCL) compared with baseline
as predicted by the change in electrical restitution (See Figure 3A), PCL=110 ms this example. B, The longest PCL which resulted in alternating action potentials (alternans threshold) was longer in the MEHP-treated hearts (P=0.06). C, Hearts after MEHP exposure became more susceptible to spontaneous arrhythmia as shown
by a higher incidence of both premature ventricular contractions (PVC) and ventricular tachycardia or ventricular fibrillation (VT/VF) following electrophysiological
study (P<0.0001, χ2 test). N=8 for each group. AUF indicates arbitrary units of fluorescence; and Ctrl, control.

prolonged with time in both groups (Figure 3D), with
no difference between APD90 and AP triangulation
(Figures 3E and 3F, respectively). At a slower PCL (240
ms), APD90 was significantly prolonged in MEHPtreated hearts (93.5±3.5 ms) compared with controls
(75.2±4.2 ms, P=0.02) (Figure 3G). The lengthening
of APD90 (Figure 3I) without a significant change in
APD30 (Figure 3H) led to an increase in the AP triangulation (APD90–APD30)53; AP triangulation was
56.6±4.5 ms in the controls and increased to 70.3±2.9
ms in the MEHP group (Figure 3J). These results suggest that MEHP exposure exerts a reverse use-dependence effect, wherein myocyte refractoriness and
action potential prolongation is increased at slower
heart rates.65

alternans or sequential beat-to-beat variations in APD,
such as displayed in Figure 4A. The threshold of electrical alternans was observed in MEHP-treated hearts at
a cycle length of 122±11 ms compared with 96±6 ms
PCL (P=0.06, Figure 4B). Rodent hearts are resistant to
fibrillation, due in part to the small tissue mass.44 Therefore, to assess arrhythmia susceptibility, each individual
heart was scored by the most severe electrical disturbance encountered during the electrophysiology study
at the end of the experiment. Arrhythmia incidence was
significantly increased in MEHP-treated hearts, compared with controls (P<0.05, Figure 4C).

Electrical Alternans and Arrhythmia
Susceptibility

Our previous in vitro studies suggest that phthalate
esters uncouple neighboring cardiomyocytes, resulting
in slowed conduction and an arrhythmogenic phenotype.40 To test whether this effect was observed in an
intact heart, CV across the epicardial surface was measured using optical mapping and a unipolar, cathodal
pacing electrode. The electrode was centered in the
field of view, and 10° increments were used to measure

AP triangulation, reverse use dependence, and a monophasic electrical restitution curve with no plateau phase
have been associated with an increased propensity for
electrical alternans and arrhythmias.53,54,66 APD instability was assessed by quantifying the incidence of electrical

MEHP Exposure Slows Conduction
Velocity
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Figure 5. Activation maps and measured conduction velocity (CV) after mono-2-ethylhexyl phthalate (MEHP) exposure.
A, Each pixel on the heart was assigned an activation time based on the maximum upstroke velocity in the fluorescent signal to create an isochrone map. Wavefronts are visible emanating from the center of the left ventricular epicardium where the cathodal pacing electrode was placed. B, After 30-min control (Ctrl)media perfusion, the activation maps did not show significant differences. C, In Ctrl hearts, analysis of the pacing site (R1) and a distal site (R2) did not show significant differences in conduction time when compared between baseline and 30-min perfusion. D, Pre-MEHP baseline showed similar CV as the Ctrl baseline. E,
After 30-min of MEHP exposure, the activation maps changed in morphology. F, Analysis of the pacing site (R1) and distal site (R2) indicated a decreased upstroke
velocity after 30-min of MEHP exposure. G, CV was significantly slower in MEHP-treated hearts compared with Ctrls after 30 min at both pacing cycle length
(PCL)=240 ms (P<0.05) and (H) PCL=140 ms (P<0.05), with N=5 per group. I, Sodium current (INa) was measured with HEK293 (human embryonic kidney 293) cells
which stably express Nav1.5. Fast sodium current (INa) was measured in the absence of anemone toxin, and half-maximal inhibition concentration (IC50) was determined at 874 µmol/L. Late sodium current (INaL) was activated with anemone toxin, and corresponding IC50 was determined at 231 µmol/L (N=5 for each group).

≥180° of coverage for longitudinal and transverse CV
measurements. Optical mapping confirmed that paced
beats propagated as elliptical wavefronts that emanated from the pacing electrode (Figures 5A through
5D). For depiction, we show 2 selected regions for each
heart across the epicardial surface and the conduction time from pacing initiation to the distal site under
control (Figure 5E) and MEHP (Figure 5F) conditions. To
investigate CV restitution, both a slow (240 ms) and
fast (140 ms) PCL were selected for CV measurements.
Incidentally, CV increased slightly between baseline and
30-minute timed recordings in control hearts at both
pacing rates (Figures 5G and 5H). However, MEHP-

treated hearts displayed 47% slower CV at 240 ms PCL
(Figure 5G) and 42% slower CV at 140 ms PCL (Figure 5H) compared with time-matched controls.

MEHP Inhibits Sodium Channel Current
Slowed myocardial CV can be attributed to a reduction in sodium channel current, anatomic obstacles,
or diminished cellular coupling (eg, gap junctions).
Because the latter 2 mechanisms may take additional
time (exceeding 30-minute chemical exposure), we
focused our attention on the direct effects of MEHP
on sodium current. The onset of current suppression
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was concentration-dependent (Figure 5I). MEHP suppressed fast and late sodium current (INa) with an IC50
of 874 µmol/L and 231 µmol/L, respectively. Tetrodotoxin (30 µmol/L), a potent neurotoxin that blocks
Nav1.5, served as a positive control resulting in >96%
inhibition for all experiments (data not shown). Using
in silico modeling combined with IC50 values, 60 µM
MEHP is expected to decrease dV/dt by 4.6% (215
to 205 mV/ms), based on a human epicardial action
potential at basic cycle length of 250 ms.

DISCUSSION

Downloaded from http://ahajournals.org by on August 6, 2021

This study is the first to examine the impact of MEHP
on the electrophysiology of the intact heart, using a
clinically relevant concentration that was comparable
to patient exposure after an exchange transfusion procedure13 or measured levels in stored blood products.4,42
Importantly, we show that acute MEHP exposure results
in slowed atrioventricular conduction, slowed epicardial CV, and increased atrioventricular and ventricular
refractory periods. Optical mapping studies revealed
a prolonged APD at slower PCLs, akin to reverse use
dependence. MEHP-treated hearts also displayed a
triangulated action potential and a steeper electrical
restitution curve—both of which have been associated
with an increased propensity for electrical alternans and
arrhythmias.

Automaticity and Sinus Node Function
Automaticity in the isolated heart is determined by a
balance between inward and outward currents (voltage
clock)67–69 and calcium oscillations (calcium clock),70 and
as such, alterations in the spontaneous beating rate can
serve as a cumulative index of cardiac excitability. Previous studies have reported bradycardia after phthalate exposure in vivo39 (>20 mg/kg MEHP), in vitro71 (10
µM DEHP), and using an isolated heart model72 (250
µM DEHP). In the current study, we observed comparable heart rates between treatment groups (control,
MEHP) at the dose and duration chosen for the study
(60 µM MEHP, 30 minutes). Alterations in automaticity may become more pronounced after longer treatment times, with higher concentrations, or exposure
to the parent compound versus metabolite (DEHP versus MEHP). We also examined beat rate variability as a
cumulative index of automaticity and sinus node discharge. Both root means successive square difference
and SD of the normal RR intervals trended higher in
MEHP-treated hearts, but neither parameter was statistically significant. Sinus node function was directly
measured using a pacing protocol to quantify sinus
node recovery time, which was significantly delayed
by 54% in MEHP-treated hearts. These results suggest
an underlying effect of phthalate esters on potassium

channel current or calcium handling in the sinoatrial
node74; indeed, alterations in calcium cycling and contractility have been reported in cardiac preparations
treated with phthalate esters.36,41

Atrioventricular Conduction
We assessed the direct effect of MEHP exposure on intrinsic atrioventricular electrical conduction, by quantifying
PR interval, AVNERP, and WBCL. Similar to a previous
report by Aronson et al,72 we observed a 44% prolongation of PR interval time in MEHP-treated hearts compared with controls—concomitant with a 37% increase
in AVNERP and 23% increase in WBCL. Negative dromotropy through the atrioventricular node is commonly
observed with cholinergics, and at least 1 study has
shown that the effects of phthalate esters on human
atrial trabeculae are partially inhibited by atropine,
suggesting an interaction with cholinergic receptors.36
Alternatively, an interaction between phthalate esters
and potassium or calcium channels could also alter nodal conduction. Indeed, a recent whole-cell patch clamp
study demonstrated that phthalate exposure (10–100
µM DEHP, parent compound of MEHP) blocks L-type calcium channels in vascular smooth muscle cells.74

Ventricular Conduction and Electrical
Instability
Using an isolated intact heart preparation, we
observed significant effects on ventricular conduction and repolarization. During sinus rhythm, MEHPtreatment prolonged RJpoint and RT intervals, indicating
a slowing of the internal conduction system. Notably,
recent studies have highlighted the utility of APD and
VERP measurements as precise indicators of ventricular repolarization.63 Using an epicardial pacing protocol, we observed a 51% increase in VERP and 24%
increase in APD90 time at slower PCL. On the surface,
this result might suggest a beneficial, antiarrhythmic
effect of acute MEHP exposure. Though importantly,
APD prolongation is a key contributor to electrical
instability when the AP is triangulated53,66—as is the
case with pharmaceuticals that exert off-target effects
on potassium channels encoded by hERG, which can
set the stage for early afterdepolarizations and Torsades.75 Moreover, reverse-use dependence can also be
proarrhythmic as the APD restitution slope changes
shape and becomes steeper. Similar to the effects of
sotalol on electrical restitution,76 we observed significant APD90 prolongation at slower PCL (>190 ms) and
a steep, monophasic APD restitution curve in MEHPtreated hearts. A steeper APD restitution slope with
lack of plateau phase at longer basic cycle lengths can
lead to an increased spatial dispersion of restitution
properties, therefore, creating a proarrhythmic milieu
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and electrical alternans.64 Due to a significant difference in VERP, we were unable to reach faster pacing
rates in MEHP-treated hearts, but electrical alternans
were observed at longer PCL in MEHP hearts (122 ms)
compared with controls (96 ms). We also observed
a 42% to 47% decrease in epicardial CV, which can
be partly attributed to an immediate inhibitory effect
of MEHP on sodium channels. Indeed, fast and late
sodium channel current was inhibited by MEHP (IC50
874 µmol/L and 231 µmol/L MEHP, respectively) using a
HEK293 cell line stably expressing Nav1.5. IC50 values
were subsequently used for human in silico modeling,
predicting a modest slowing of dV/dt. Though the latter was more modest than anticipated, additional voltage-clamp studies using a cardiomyocyte model may
aid in the interpretation of these results.
Due to the acute nature of the observed effects of
MEHP exposure, our study suggests that phthalate esters
interfere with ionic currents in the myocardium—and
these effects may be multifactorial. Unfortunately, the
rodent myocardium is not ideal for assessing arrhythmia incidence because of its small size and robustness
to fibrillation.44 Future electrophysiological studies are
needed, in a larger animal model, to definitively draw
a conclusion on the arrhythmogenic potential of MEHP
and other phthalate esters. Clinical studies showed that
abnormal slow conduction in patients with ventricular
arrhythmias can manifest by increased power of high
frequencies within the ECG signal.62,77 In this study, we
observed a trend towards higher contribution of high
frequencies within QRS, but PSD measurements proved
difficult due to variability in excised heart positioning
relative to ECG lead placement.

Study Limitations
The scope of the study was limited to the effect of acute
(30 minutes) MEHP exposure on cardiac electrophysiology, using an isolated heart model. Such a model prevents the investigation of longer exposure time, and ex
vivo results may differ from in vivo studies with an intact
vascular and autonomic nervous system. The reported
results are also limited to the effect of MEHP, and therefore, do not account for additional effects that may be
caused by DEHP (the parent compound) or other secondary metabolites. The presented study was also limited to a single dose of MEHP, which was chosen based
on the reported blood concentration after an exchange
transfusion procedure.

Conclusions
This study reports the electrophysiological effects of
MEHP on intact, isolated rodent hearts. The increase in
action potential triangulation and altered APD restitution
curve are both indicators of increased arrhythmic risk.
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